Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data
M P Coleman,D Forman,H Bryant,J Butler,B Rachet,C Maringe,U Nur,E Tracey,M Coory,J Hatcher,C E McGahan,D Turner,L Marrett,M L Gjerstorff,T B Johannesen,J Adolfsson,M Lambe,G Lawrence,D Meechan,E J Morris,R Middleton,J Steward,M A Richards,ICBP Module 1 Working Group,Ole Andersen,Heather Bryant,David Currow,Anna Gavin,Gunilla Gunnarsson,Jane Hanson,David Hill,Stein Kaasa,Lone de Neergaard,Michael A Richards,Terry Sullivan,Jan Adolfsson,Michael Coory,David Forman,Marianne L Gjerstorff,Tom Borge Johannesen,Mats Lambe,David Meechan,Richard Middleton,Janey Shin,John Steward,Elizabeth Tracey,Juanita Hatcher,Carol Russell,Andy Coldman,Mark Elwood,David Levy,Colleen E McGahan,Dhali Dhaliwal,Donna Turner,Loraine Marrett,John McLaughlin,Kamini Milnes,Diane Nishri,Michael Sherar,Gerda Engholm,Eva J Morris,James Thomas,Karen Linklater,Rebecca Elleray,Andy Smith,Gill Lawrence,Finian Bannon,Colin Fox,Ceri White,Jonas Bergh,John Boyages,Michel Boyer,John Butler,Peter Clark,Bill Evans,Hilary Fielder,Tony Fields,Paul Finan,Tommy Fornander,Neville Hacker,Louise Hanna,Thomas Hogberg,Charlotte Hosbond,Karl Kölbeck,Martin Lee,Peter Barrett Lee,Jason Lester,Mark Levine,Gudrun Lindmark,Tim Maughan,Usha Menon,Ian Moneypenny,Andy Nordin,Julietta Patnick,Mick Peake,Andrew Radcliffe,Barry Rosen,Annika Sjövall,Allan Spigelman,Gunnar Wagenius,Fredrik Wärnberg,Michael Williams,Ian Williamson,Claudia Allemani,Michel P Coleman,Libby Ellis,Camille Maringe,Ula Nur,Manuela Quaresma,Bernard Rachet,Sarah Walters
DOI: https://doi.org/10.1016/S0140-6736(10)62231-3
2011-01-08
Abstract:Background: Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional and international differences in survival represent many avoidable deaths. Differences in survival have prompted or guided cancer control strategies. This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival. Methods: Data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995-2007, with follow-up to Dec 31, 2007. Data quality control and analyses were done centrally with a common protocol, overseen by external experts. We estimated 1-year and 5-year relative survival, constructing 252 complete life tables to control for background mortality by age, sex, and calendar year. We report age-specific and age-standardised relative survival at 1 and 5 years, and 5-year survival conditional on survival to the first anniversary of diagnosis. We also examined incidence and mortality trends during 1985-2005. Findings: Relative survival improved during 1995-2007 for all four cancers in all jurisdictions. Survival was persistently higher in Australia, Canada, and Sweden, intermediate in Norway, and lower in Denmark, England, Northern Ireland, and Wales, particularly in the first year after diagnosis and for patients aged 65 years and older. International differences narrowed at all ages for breast cancer, from about 9% to 5% at 1 year and from about 14% to 8% at 5 years, but less or not at all for the other cancers. For colorectal cancer, the international range narrowed only for patients aged 65 years and older, by 2-6% at 1 year and by 2-3% at 5 years. Interpretation: Up-to-date survival trends show increases but persistent differences between countries. Trends in cancer incidence and mortality are broadly consistent with these trends in survival. Data quality and changes in classification are not likely explanations. The patterns are consistent with later diagnosis or differences in treatment, particularly in Denmark and the UK, and in patients aged 65 years and older. Funding: Department of Health, England; and Cancer Research UK.